SCHEMBL26103457

SCHEMBL26103457

O=C1NC(NC2CCCCCC2)=N/C1=C\c1ccc2nnsc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 16/20 0.54
▸ CLK4 Q9HAZ1 16/20 0.54
▸ DYRK1A Q13627 16/20 0.54
▸ DYRK1B Q9Y463 15/20 0.54
▸ CLK2 P49760 14/20 0.54
▸ DYRK3 O43781 13/20 0.54
▸ CLK3 P49761 9/20 0.54
▸ DYRK2 Q92630 13/20 0.44
▸ DYRK4 Q9NR20 7/20 0.44
▸ GSK3B P49841 5/20 0.44
▸ CSNK1E P49674 1/20 0.40
▸ PIM1 P11309 2/20 0.39
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2B P67870 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ CSNK2A3 Q8NEV1 1/20 0.39
▸ CDK5 Q00535 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ PRMT3 O60678 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30494174 1.00 CLK1 (0.54) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL26103452 1.00 CLK1 (0.54) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL30494160 1.00 CLK1 (0.54) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL23970231 0.84 CLK1 (0.64) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL23970214 0.84 CLK1 (0.64) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL23970258 0.84 CLK1 (0.64) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL23970070 0.82 CLK1 (0.65) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL30144911 0.82 CLK1 (0.55) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL30144887 0.82 CLK1 (0.55) CLK1CLK4DYRK1ADYRK1BCLK2
SCHEMBL25257875 0.82 CLK1 (0.55) CLK1CLK4DYRK1ADYRK1BCLK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 — — US claimed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO claimed
WO-2023072966-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 CLK1, CLK2, CLK3 CLK1 1/4885CLK4 4/4885DYRK1A 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback